Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia.

ABSTRACT: Background: Everolimus is an inhibitor of mammalian target of rapamycin complex 1. As mutations in TSC1 and TSC2, which cause partial-onset seizures associated with TSC, were found in focal cortical dysplasia type Ⅱ (FCD Ⅱ) patients, a clinical trial has been performed to explore the efficacy and safety of everolimus in FCD patients. However, no dosage regimen was determined to treat FCD II. To recommend an optimal dose regimen for FCD patients, a population pharmacokinetic model of everolimus in FCD patients was developed. Methods: The data of everolimus were collected from September 2017 to May 2020 in a tertiary-level hospital in Korea. The model was developed using NONMEM^® software version 7.4.1 (Icon Development Solutions, Ellicott City, MD, Unit

SUBMITTER: Park J 

PROVIDER: S-EPMC10704167 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature